These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 23621919)
1. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma. Lv C; Ma Y; Feng Q; Fang F; Bai H; Zhao B; Yan S; Wu N; Zheng Q; Li S; Chen J; Wang J; Feng Y; Wang Y; Pei Y; Fang J; Yang Y World J Surg Oncol; 2013 Apr; 11():96. PubMed ID: 23621919 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016 [TBL] [Abstract][Full Text] [Related]
3. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Rosell R; Felip E; Taron M; Majo J; Mendez P; Sanchez-Ronco M; Queralt C; Sanchez JJ; Maestre J Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961 [TBL] [Abstract][Full Text] [Related]
4. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606 [TBL] [Abstract][Full Text] [Related]
5. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416 [TBL] [Abstract][Full Text] [Related]
6. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408 [TBL] [Abstract][Full Text] [Related]
7. First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients. Li Y; Wang LR; Chen J; Lou Y; Zhang GB Dis Markers; 2014; 2014():960458. PubMed ID: 24591771 [TBL] [Abstract][Full Text] [Related]
8. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin. Qiu ZQ; Zhao K Asian Pac J Cancer Prev; 2014; 15(17):7303-7. PubMed ID: 25227833 [TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients. Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694 [TBL] [Abstract][Full Text] [Related]
10. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. Santarpia M; Ramirez JL; de Aguirre I; Garrido P; Pérez Cano M; Queralt C; Gonzalez-Larriba JL; Insa A; Provencio M; Isla D; Camps C; Blanco R; Moran T; Rosell R; Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619 [TBL] [Abstract][Full Text] [Related]
11. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer. Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178 [TBL] [Abstract][Full Text] [Related]
12. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer. Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097 [TBL] [Abstract][Full Text] [Related]
13. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer. Lv C; Ma Y; Wu N; Yan S; Zheng Q; Sun Y; Li S; Fang J; Yang Y World J Surg Oncol; 2013 Mar; 11():76. PubMed ID: 23517534 [TBL] [Abstract][Full Text] [Related]
14. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine. Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234 [TBL] [Abstract][Full Text] [Related]
15. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946 [TBL] [Abstract][Full Text] [Related]
16. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L; Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168 [TBL] [Abstract][Full Text] [Related]
17. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. Bepler G; Kusmartseva I; Sharma S; Gautam A; Cantor A; Sharma A; Simon G J Clin Oncol; 2006 Oct; 24(29):4731-7. PubMed ID: 16966686 [TBL] [Abstract][Full Text] [Related]
18. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy. Zou ZQ; Du YY; Sui G; Xu SN Asian Pac J Cancer Prev; 2015; 16(8):3189-94. PubMed ID: 25921119 [TBL] [Abstract][Full Text] [Related]
19. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. Ryu JS; Shin ES; Nam HS; Yi HG; Cho JH; Kim CS; Kim HJ; Lee JE J Thorac Oncol; 2011 Aug; 6(8):1320-9. PubMed ID: 21642870 [TBL] [Abstract][Full Text] [Related]
20. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 Zhong WZ; Chen KN; Chen C; Gu CD; Wang J; Yang XN; Mao WM; Wang Q; Qiao GB; Cheng Y; Xu L; Wang CL; Chen MW; Kang X; Yan W; Yan HH; Liao RQ; Yang JJ; Zhang XC; Zhou Q; Wu YL J Clin Oncol; 2019 Sep; 37(25):2235-2245. PubMed ID: 31194613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]